Definium Therapeutics, Inc. - Common Shares (DFTX)
DFTX moved a median of -0.03% 30 minutes after news, and +0.43% by the close. How DFTX actually reacts to news — the realized, point-in-time move the market made, measured across 122 labeled events over the last three years with zero look-ahead.
DFTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 47% | 118 |
| 30-min | -0.03% | 48% | 118 |
| 60-min | +0.09% | 55% | 118 |
| to close | +0.43% | 54% | 118 |
| Middle 50% of DFTX reactions | -3.36% to +2.00% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 122 |
Half of all Definium Therapeutics, Inc. - Common Shares news events land between -3.36% and +2.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DFTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | -0.41% | 39% | -1.44% |
| Rating reiterations | 41 | +0.16% | 56% | -0.76% |
| Price-target raises | 13 | -0.36% | 39% | -0.88% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how DFTX ranks against every other measured name →
That’s how DFTX usually reacts — get an email when it moves on news →Email me when DFTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DFTX's baseline. Nothing else.
Recent DFTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -1.46% | +0.12% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -0.47% | +0.16% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -3.36% | -7.47% | |
| Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder | Press release | Business Wire | -3.36% | -7.47% | |
| Form 8-K Definium Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -3.36% | -7.47% | |
| Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 | Press release | Business Wire | -3.36% | -7.47% | |
| Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 | Press release | Business Wire | +0.28% | +0.21% | |
| Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results | Press release | Business Wire | +0.03% | +0.60% | |
| Form 8-K Definium Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +0.60% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | +0.90% | -2.23% | |
| Definium Therapeutics to Participate at Upcoming Investor Conferences and Events | Press release | Business Wire | -0.70% | -2.15% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | +0.02% | +2.03% | |
| Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder | Press release | Business Wire | -3.14% | -8.98% | |
| Form 8-K Definium Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -3.14% | -8.98% | |
| Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Press release | Business Wire | +2.46% | -0.35% | |
| Form 10-Q Definium Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.46% | -0.35% | |
| Form 8-K Definium Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.46% | -0.35% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -0.05% | -0.77% | |
| Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | -1.91% | -3.25% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -1.05% | +6.10% | |
| Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology | Press release | Business Wire | +0.50% | -6.82% | |
| New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD) | Press release | Business Wire | -0.53% | +5.75% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -1.94% | +0.29% | |
| Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares | Press release | Business Wire | -0.25% | +0.56% | |
| Form 8-K Definium Therapeutics, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +4.07% | +6.67% | |
| Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering | Press release | Business Wire | +3.34% | +6.71% | |
| Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder | Press release | Business Wire | -0.21% | -4.78% | |
| Definium Therapeutics, Inc. Announces Proposed Public Offering | Press release | Business Wire | +2.03% | -0.88% | |
| Form 8-K Definium Therapeutics, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | -4.78% | |
| Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 | Press release | Business Wire | -0.21% | -4.78% | |
| Form S-8 Definium Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.08% | +1.20% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | +1.44% | +2.16% | |
| Form 8-K Definium Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -4.04% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -0.76% | -2.93% | |
| Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | +0.43% | +8.89% | |
| Form 8-K Definium Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -1.72% | |
| Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder | Press release | Business Wire | -1.12% | -1.17% | |
| Form 8-K Definium Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | -1.17% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -1.12% | -1.17% | |
| Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Press release | Business Wire | -4.18% | -3.54% | |
| Form 10-Q Definium Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.18% | -3.54% | |
| Form 8-K Definium Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.18% | -3.54% | |
| Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | +0.14% | -1.63% | |
| Form DEF 14A Definium Therapeutics, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +1.54% | +2.11% | |
| Form DEFA14A Definium Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.54% | +2.11% | |
| Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day | Press release | Business Wire | -0.35% | +1.44% | |
| Form 8-K Definium Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | +1.44% | |
| Definium Therapeutics Announces New Employee Inducement Grants | Press release | Business Wire | -2.90% | +0.38% | |
| Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments | Press release | Business Wire | -5.34% | -9.70% | |
| Definium Therapeutics to Participate at Upcoming Investor Conferences and Events | Press release | Business Wire | -0.24% | +1.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DFTX section they belong to.
Where else DFTX is measured.
DFTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Definium Therapeutics, Inc. - Common Shares's median reaction calculated?
Every labeled DFTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 122 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of DFTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DFTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.